- The Washington Times - Wednesday, March 17, 2004

ASSOCIATED PRESS

Scientists say an enzyme in the brain that monitors energy in cells also appears to regulate appetite and weight, a discovery that could lead to new treatments for obesity.

The enzyme is known as AMP-activated protein kinase, or AMPK. Its activity is regulated by the hormone leptin, which previously was linked to appetite suppression.

Harvard researchers found in experiments with mice that when AMPK was inhibited, the animals ate less and lost weight. When AMPK levels were boosted, the mice ate more and gained weight.

Barbara B. Kahn, the lead author of the study, said the work identifies a new leptin-signaling pathway and a promising new target in humans.

“It will affect drug development and approaches for new preventions and treatments,” Miss Kahn said.

The study appears in an online version of the journal Nature.

Dr. David Cummings, a University of Washington obesity researcher who was not involved in the work, said the findings complement recent work in Britain in which the hormone ghrelin, an appetite-stimulating hormone, also was found to affect AMPK levels.

Almost a third of American adults are obese, up from 14 percent a generation ago, according to government data. Only a few prescription weight-control drugs are on the market, and they produce only modest weight loss, either by suppressing appetite or by preventing the body from digesting and absorbing fats.

Dr. Cummings said studies show that hormone-replacement therapy won’t be a simple cure for the nation’s obesity woes. Studies on using leptin to control weight found that obese people had lost sensitivity to the hormone, Dr. Cummings said.

Copyright © 2019 The Washington Times, LLC. Click here for reprint permission.

The Washington Times Comment Policy

The Washington Times welcomes your comments on Spot.im, our third-party provider. Please read our Comment Policy before commenting.

 

Click to Read More and View Comments

Click to Hide